EyePoint (EYPT) Net Income towards Common Stockholders (2010 - 2026)

EyePoint (EYPT) reported Net Income towards Common Stockholders of -$120.2 million for Q1 2026, down 129.33% on a YoY basis from $409.9 million in Q1 2025, and down 77.79% sequentially from -$67.6 million in Q4 2025.

EyePoint (EYPT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

EyePoint (EYPT) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$120.2 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 129.33% year-over-year to -$120.2 million; the trailing twelve-month figure through Mar 2026 stood at -$307.0 million (down 99.33% YoY), and the FY2025 full-year result was -$232.0 million, down 77.25% from the prior year.
  • Net Income towards Common Stockholders fell to -$120.2 million in Q1 2026, from -$67.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$16.3 million in Q4 2023 to a low of -$120.2 million in Q1 2026.
  • A 5-year average of -$53.2 million and a median of -$44.4 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 643.39% in 2022 and jumped 72.55% in 2023, its largest moves.
  • Tracing EYPT's Net Income towards Common Stockholders over 5 years: stood at -$44.4 million in 2022, then surged by 63.2% to -$16.3 million in 2023, then plunged by 153.5% to -$41.4 million in 2024, then plunged by 63.31% to -$67.6 million in 2025, then tumbled by 77.79% to -$120.2 million in 2026.
  • Business Quant data shows EYPT's Net Income towards Common Stockholders at -$120.2 million in Q1 2026, -$67.6 million in Q4 2025, and -$59.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 EyePoint 1.07 Mn -221.48 Mn 168,000.00 -120.20 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -120.20 Mn
Dec 31, 2025 -67.61 Mn
Sep 30, 2025 -59.73 Mn
Jun 30, 2025 -59.43 Mn
Mar 31, 2025 -52.42 Mn
Dec 31, 2024 -41.40 Mn
Sep 30, 2024 -29.36 Mn
Jun 30, 2024 -30.83 Mn
Mar 31, 2024 -98.09 Mn
Dec 31, 2023 -16.33 Mn
Sep 30, 2023 -24.84 Mn
Jun 30, 2023 -35.03 Mn
Mar 31, 2023 -22.31 Mn
Dec 31, 2022 -44.38 Mn
Sep 30, 2022 -90.48 Mn
Jun 30, 2022 -91.85 Mn
Mar 31, 2022 -19.53 Mn
Dec 31, 2021 -19.92 Mn
Sep 30, 2021 -16.70 Mn
Jun 30, 2021 -12.36 Mn